Literature DB >> 20737012

Efficacy and Safety Profile of Solvent/Detergent Plasma in the Treatment of Acute Thrombotic Thrombocytopenic Purpura: A Single-Center Experience.

Elvira Edel1, Haifa Kathrin Al-Ali, Susanne Seeger, Dörte Kauschat, Gert Matthes.   

Abstract

BACKGROUND: Thrombotic thrombocytopenic purpura (TTP) is a rare clinical disorder which was associated with poor prognosis for a long time. The outcome has been improved by the consistent introduction of thera-peutic plasma exchange (TPE) as standard treatment of TTP. PATIENTS AND METHODS: We describe our experience in the use of solvent/detergent-treated plasma (SDP) for TPE in TTP. We retrospectively analyzed acute TTP epi-sodes in 8 patients (mean age = 27 years, range 18-44 years) treated with TPE using SDP with regard to tolerability and efficacy.
RESULTS: All 8 patients were positive for anti-ADAMTS-13 antibody. Seven out of 8 had a se-vere ADAMTS-13 deficiency. All patients responded rapidly to SDP TPE with an increase in platelet count to above 150 x 10(9)/l. Hemolytic anemia disappeared over the treatment period. Approximately 2,000 l SDP were used for more than 500 treatments. Treatment with SDP was well tolerated; none of the patients experienced an adverse drug reaction after exposure to SDP. No major complications occurred even after multiple TPE.
CONCLUSION: Our investigations suggest that TPE using SDP as replacement fluid is an effective treatment for TTP. The data described also indicate that SDP might offer the benefit of reducing adverse drug reactions.

Entities:  

Year:  2010        PMID: 20737012      PMCID: PMC2914404          DOI: 10.1159/000264996

Source DB:  PubMed          Journal:  Transfus Med Hemother        ISSN: 1660-3796            Impact factor:   3.747


  42 in total

1.  The Norwegian Plasma Fractionation Project--a 12 year clinical and economic success story.

Authors:  O Flesland; J Seghatchian; B G Solheim
Journal:  Transfus Apher Sci       Date:  2003-02       Impact factor: 1.764

2.  Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias.

Authors:  Sarah L Allford; Beverley J Hunt; Peter Rose; Samuel J Machin
Journal:  Br J Haematol       Date:  2003-02       Impact factor: 6.998

3.  Cryoprecipitate poor plasma does not improve early response in primary adult thrombotic thrombocytopenic purpura (TTP).

Authors:  Z R Zeigler; R K Shadduck; J F Gryn; P B Rintels; J N George; E C Besa; D Bodensteiner; B Silver; R E Kramer
Journal:  J Clin Apher       Date:  2001       Impact factor: 2.821

4.  Therapeutic plasma exchange: complications and management.

Authors:  M H Mokrzycki; A A Kaplan
Journal:  Am J Kidney Dis       Date:  1994-06       Impact factor: 8.860

5.  Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group.

Authors:  G A Rock; K H Shumak; N A Buskard; V S Blanchette; J G Kelton; R C Nair; R A Spasoff
Journal:  N Engl J Med       Date:  1991-08-08       Impact factor: 91.245

6.  Inhibitors of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura.

Authors:  H M Tsai; A Li; G Rock
Journal:  Clin Lab       Date:  2001       Impact factor: 1.138

7.  Solvent/detergent fresh frozen plasma as primary treatment of acute thrombotic thrombocytopenic purpura.

Authors:  G Evans; C Llewelyn; R Luddington; T P Baglin; L M Williamson
Journal:  Clin Lab Haematol       Date:  1999-04

8.  Laboratory abnormalities in thrombotic thrombocytopenic purpura. Canadian Apheresis Group.

Authors:  G Rock; J G Kelton; K H Shumak; N A Buskard; D M Sutton; W B Benny
Journal:  Br J Haematol       Date:  1998-12       Impact factor: 6.998

9.  Effects of fresh-frozen plasma and its cryosupernatant fraction on von Willebrand factor multimeric forms in chronic relapsing thrombotic thrombocytopenic purpura.

Authors:  J L Moake; J J Byrnes; J H Troll; C K Rudy; S L Hong; M J Weinstein; N M Colannino
Journal:  Blood       Date:  1985-05       Impact factor: 22.113

10.  von Willebrand factor cleaving protease and ADAMTS13 mutations in childhood TTP.

Authors:  Reinhard Schneppenheim; Ulrich Budde; Florian Oyen; Dorothea Angerhaus; Volker Aumann; Elke Drewke; Wolf Hassenpflug; Johannes Häberle; Karim Kentouche; Elisabeth Kohne; Karin Kurnik; Dirk Mueller-Wiefel; Tobias Obser; René Santer; Karl-Walter Sykora
Journal:  Blood       Date:  2002-10-17       Impact factor: 22.113

View more
  5 in total

1.  As for the Past, as for 2010.

Authors:  Peter Schlenke; Walter Sibrowski
Journal:  Transfus Med Hemother       Date:  2010-02       Impact factor: 3.747

2.  Safety and tolerability of solvent/detergent-treated plasma for pediatric patients requiring therapeutic plasma exchange: An open-label, multicenter, postmarketing study.

Authors:  Cassandra D Josephson; Stuart Goldstein; David Askenazi; Claudia S Cohn; Philip C Spinella; Ara Metjian; Ross M Fasano; Lejla Music-Aplenc
Journal:  Transfusion       Date:  2021-12-20       Impact factor: 3.337

3.  Changes in plasma von Willebrand factor and von Willebrand factor cleaving protease in thrombotic thrombocytopenic purpura: A case report.

Authors:  Yu Gao; Liping Wang; Guangxian Nan
Journal:  Exp Ther Med       Date:  2017-10-24       Impact factor: 2.447

4.  Transition from fresh frozen plasma to solvent/detergent plasma in the Netherlands: comparing clinical use and transfusion reaction risks.

Authors:  Nicholas H Saadah; Martin R Schipperus; Johanna C Wiersum-Osselton; Marian G van Kraaij; Camila Caram-Deelder; Erik A M Beckers; Anja Leyte; Jan M M Rondeel; Karen M K de Vooght; Floor Weerkamp; Jaap Jan Zwaginga; Johanna G van der Bom
Journal:  Haematologica       Date:  2019-07-04       Impact factor: 9.941

5.  Solvent/detergent plasma: pharmaceutical characteristics and clinical experience.

Authors:  Giancarlo Maria Liumbruno; Massimo Franchini
Journal:  J Thromb Thrombolysis       Date:  2015-01       Impact factor: 2.300

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.